Clinic Roundup

Infinity Pharmaceuticals Inc., of Cambridge, Mass., completed enrollment in a Phase II trial of IPI-926 for pancreatic cancer. The trial has enrolled 122 patients and will compare IPI-926 in combination with gemcitabine to placebo and gemcitabine with a primary endpoint of overall survival.